<DOC>
	<DOCNO>NCT02776202</DOCNO>
	<brief_summary>Sickle cell disease ( SCD ) common inherit blood disorder Saudi Arabia . Its clinical severity widely heterogeneous among patient share genetic mutation . Severe frequent pain crisis , recurrent acute chest syndrome stroke feature severe SCD . Hydroxyurea effective treatment SCD ameliorate severity frequency pain crisis acute chest syndrome decrease mortality , however , less effective prevention treatment stroke end organ dysfunction . The readily available cure SCD hematopoietic stem cell transplantation ( HSCT ) . Most child SCD treat HSCT receive myeloablative conditioning excellent result . The application reduce intensity ( RIC ) non-myeloablative ( NMA ) conditioning regimen reserve patient old 16 year age increase risk morbidity mortality HSCT6 . However , infertility gonadal failure myeloablative conditioning important barrier willingness patient family undergo HSCT . The development effective RIC HSCT SCD might spare fertility SCD patient would obvious merit . With ultimate goal expand curative therapy SCD patient , propose investigate HSCT RIC condition regimen . We carry pilot study HSCT HLA match sibling donor use thymoglobulin/fludarabine/melphalan condition sirolimus mycophenolate mofetil ( MMF ) GVHD prophylaxis SCD patient severe complication stroke severe complication . We hypothesize HSCT HLA match sibling use thymoglobulin/fludarabine/melphalan condition SCD maintain level stable donor chimerism sufficient cure SCD minimal toxicity .</brief_summary>
	<brief_title>HLA-Identical Sibling Donor Bone Marrow Transplantation Individuals With Severe Sickle Cell Disease Using Reduced Intensity Conditioning Regimen</brief_title>
	<detailed_description>Busulfan-based myeloablative allogeneic HSCT HLA-matched related donor child associate high cure rate range 80-90 % different trial , review 6 . Lessons learn trial include ; rabbit ATG significantly contribute low graft rejection rate , presence stable mixed chimerism sufficient cure SCD , risk neurological toxicity minimize maintain platelet count great 50,000/uL hemoglobin level 9-11g/dL , add phenytoin prophylaxis , prevent hypertension hypomagnesemia . We present result trial , focus proposal investigate use NMA/RIC HSCT SCD . 2.1 RIC/NMA HSCT SCD : 1 . Van Besien et al 8 report transplant result two adult SCD underwent allogeneic transplantation HLA-identical sibling donor conditioning fludarabine/melphalan ATG . One patient 40-year-old female significant end-organ dysfunction relate SCD ( renal failure treat dialysis , pulmonary diffusion capacity reduce 25 % ischemic stroke ) heavily transfuse prior transplant . She also RBC alloantibody receive hydroxyurea erythropoietin . She condition ATG 30 mg/kg 4 consecutive day ( day -5 day -2 ) , fludarabine 30 mg/m2 i.v . 4 consecutive day ( day -5 day -2 ) melphalan 140 mg/m2 i.v . day -1 . The patient hemodialysis perform day -5 , day -3 day -1 chemotherapy administer . On day 0 , patient receive infusion cryopreserved G-CSF-mobilized peripheral blood stem cell ( PBSC ) . GVHD prophylaxis consist daily tacrolimus mini methotrexate regimen ( 5 mg/m2 give day 1 , 3 6 ) . There successful neutrophil platelet engraftment 100 % stable chimerism . She develop interstitial pneumonia , possibly secondary GVHD , 140 day transplantation progress respiratory failure lead death day 355 . The second patient 56 year old SC disease heavily pretransfused multiple SCD complication . She receive conditioning , GVHD prophylaxis , PBSC source first patient . She 100 % donor chimerism die day 142 secondary TTP severe gut GVHD CNS infection . 2 . Iannone et al 9 describe 6 pediatric patient SCD underwent bone marrow transplant HLA match sibling condition fludarabine 50mg/m2/day 3-5 day 200 cGy TBI addition horse ATG one patient . GVHD prophylaxis include MMF tacrolimus cyclosporine various taper schedule . There minimal toxicity , however , patient develop graft rejection upon taper immunosuppressive medication . 3 . Horan et al 10 describe three SCD patient heavily transfuse prior transplant underwent HLA match sibling transplant conditioning fludarabine 25mg/m2 5 consecutive day transplantation ( day -6 -2 ) , rabbit ATG ( Thymoglobulin ) 4 consecutive day transplantation ( day -6 -2 ) age adjust dose , single dose TBI 200 cGy . GVHD prophylaxis include MMF first three month CSA least six month . All graft rejection except one immunosuppression taper . There GVHD . 4 . Horwitz et al 11 report outcome two adult SCD patient underwent HLA match sibling transplant PBSC source graft case . Conditioning TBI 200 cGy follow fludrabine 24-30 mg/m2 4 day cyclophosphamide 500 mg/m2 four day alemtuzumab 100mg five day . MMF give first 100 day post transplant . Both engraft successfully GVHD follow 20 month . 5 . Krishnamurti et al describe use RIC seven SCD patient , age range 6-16 year . The conditioning busulfan 3.2 mg/kg day -8 -7 , fludarabine 35mg/m2 day -6 -2 , equine ATG 30mg/kg day -5 -1 , total lymphoid irradiation . GVHD prophylaxis CSA MMF . CSA taper start day +180 MMF taper vary +45 +220 day . Six patient stable mixed chimerism stop CSA MMF . One patient late graft failure . There low rate GVHD . 6 . Hsieh et al report use non-myeloablative conditioning SCD patient older 16 year age . Graft source GCSF mobilize PBSC HLA match sibling least 10 X106 CD34/kg recipient weight . Conditioning alemtuzumab ( total 1mg/kg divide day -7 -3 ) single dose TBI 300 cGy day -2 . Presence major ABO incompatibility one exclusion criterion study . Sirolimus use GVHD prophylaxis prevent graft rejection . Nine 10 patient engraft successfully stable chimerism , however , patient continue sirolimus . None patient GVHD . They recently update promising result total 30 patient able taper sirolimus 15 patient . 2.2 Rationale use thymoglobulin/fludarabine/melphalan condition RIC feasible option patient SCD successfully cure disease . A pre-transplant backbone regimen consist Alemtuzumab ATG , fludarabine , melphalan apply successfully SCD patient describe . We anticipate toxicity risk lower full myeloablative conditioning use busulfan cyclophosphamide ( BU/CY ) . Melphalan report cause infertility , mostly use chemotherapy agent . The use melphalan alone condition regimen report potentially preserve fertility woman . So regimen could potentially preserve fertility high rate compare BU/CY . 2.3 Rationale pre-transplant immunosuppression therapy hydroxyurea Individuals hemoglobinopathies general adequate T cell function active bone marrow lead high risk graft rejection especially among patient heavily transfuse . Experience class 3 thalassemia patient show pretreatment hydroxyurea , azathioprine , fludarabine decrease risk graft rejection allow use low dose cyclophosphamide . So use hydroxyurea prior transplant minimize risk graft rejection associate RIC sickle cell anemia . 2.4 Rationale use sirolimus MMF GVHD prophylaxis : Post-grafting immunosuppression appear crucial ensure stable engraftment ; early taper appear contribute late graft rejection several series . Sirolimus inhibitor mammalian target rapamycin ( mTOR ) induce immune tolerance use successfully GVHD prophylaxis adult SCA patient underwent RIC/ NMA . Sirolimus combination calcineurin inhibitor MMF utilize effectively pediatric patient 19-21 . However , study show increase risk veno-occlusive disease combination sirolimus MMF increase risk transplant-associated thrombotic microangiopathy combine tacrolimus especially among patient receive busulfan-based conditioning 22-24 . We use RIC regimen anticipate combination sirolimus MMF cause excess toxicity .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . SCD patient 318 year old . 2 . SCD ( HbSS , HbSβ° thalassemia genotype ) least one follow condition : 1 . Clinically significant neurologic event ( stroke ) neurologic defect last &gt; 24 hour accompany infarct cerebral magnetic resonance imaging ( MRI ) 2 . Minimum two episode acute chest syndrome within precede 2year period define new pulmonary alveolar consolidation involve least one complete lung segment ( associate acute symptom include fever , chest pain , tachypnea , wheeze , rale cough attribute asthma bronchiolitis ) despite adequate supportive care measure 3 . History 3 severe pain event per year 2 year prior enrollment . 3 . Availability 10/10 genotypically HLA identical relate donor 4 . In patient treated regular RBC transfusion &gt; 12 month , liver biopsy show evidence cirrhosis active hepatitis 5 . Patients must Karnofsky score ≥ 50 WHO/ECOG ≥ 2 patient age ≥ 16 , Lansky score ≥ 50 patient age &lt; 16 . 6 . Adequate cardiac function : shortening fraction &gt; 25 % ejection fraction &gt; 55 % echocardiogram 7 . Adequate renal function : serum creatinine within normal limit creatinine clearance &gt; 70 ml/min/1.73 m2 8 . Adequate liver function : Total bilirubin within normal limit AST/ALT &lt; 2.5x upper limit normal 1 . Patients symptomatic cardiac insufficiency arrhythmia . 2 . Patients cirrhosis liver biopsy . 3 . Hepatitis B , hepatitis C , HIV seropositive patient . 4 . Patients disease would increase toxicity transplant .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>